Wall Street Zen downgraded shares of GlucoTrack (NASDAQ:GCTK – Free Report) to a strong sell rating in a research note released on Saturday morning.
Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GlucoTrack in a research report on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, GlucoTrack presently has an average rating of “Sell”.
View Our Latest Stock Report on GCTK
GlucoTrack Trading Down 16.9%
Hedge Funds Weigh In On GlucoTrack
Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its holdings in GlucoTrack by 102,125.0% in the second quarter. Bank of America Corp DE now owns 4,089 shares of the company’s stock worth $25,000 after purchasing an additional 4,085 shares during the period. Boothbay Fund Management LLC acquired a new stake in shares of GlucoTrack during the fourth quarter worth $52,000. Finally, Ikarian Capital LLC bought a new position in shares of GlucoTrack in the 4th quarter worth about $177,000. 10.92% of the stock is currently owned by institutional investors.
About GlucoTrack
GlucoTrack, Inc, a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc and changed its name to GlucoTrack, Inc in November 2021. GlucoTrack, Inc was founded in 2001 and is based in Rutherford, New Jersey.
See Also
- Five stocks we like better than GlucoTrack
- The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence
- Is Domino’s Stock Serving Up a Buying Opportunity?
- A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free
- Why Gold Miners Could Be the Market’s Biggest Comeback Story
Receive News & Ratings for GlucoTrack Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlucoTrack and related companies with MarketBeat.com's FREE daily email newsletter.
